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Introduction
Mutations of ADA2 have been recently reported as cau-
sative of an inflammatory condition characterized by
polyarteritis, cerebral stroke and immunodeficiency; the
response to immunosuppressors and biologic drugs is
not univocal.
Objectives
To describe a series of patients with DADA2, focusing
on the response to treatment.
Methods
We retrospectively collected the clinical course and
response to treatment of three paediatric patients with
DADA2.
Results
A boy born from non-consanguineous parents at the age
of 2 years presented with livedo reticularis associated to
elevation of acute phase reactants and recurrent episodes
of arthralgia, fever and hypertension responsive to predni-
sone. At the age of 6 years he presented a haemorrhagic
stroke of the left temporal lobe. A skin biopsy was consis-
tent with a diagnosis of polyarteritis. The patient presented
good response to thalidomide. Low immunoglobulins
levels were then detected,.Two years later, treatment was
discontinued with a prompt recurrence of the symptoms,
requiring high dose steroids. Etanercept was then started
(25 mg/week) with normalisation of both clinical picture
and laboratory parameters. The levels of plasmatic immu-
noglobulins slowly normalized. Even the hypertension
improved. The molecular analysis of the CECR1 gene
revealed the presence of two heterozygous mutations
(R312X and E328D). After five years of treatment the
patient is in wellbeing. The younger brother of the above
patient at the age of 9 months presented with livedo
reticularis, hypertension, reduction of plasmatic immuno-
globulin levels and elevation of acute phase reactants,
responsive to short steroidal course. At the age of one year
the child showed intestinal ischemia, secondary to
vasculitis, consistent with PAN. After few months the
patient presented a stroke with hemiplegia. Treatment
with thalidomide controlled the clinical picture for two
years, but was then discontinued due to a reduced nerve
conduction velocity. Soon after discontinuation livedo
reticularis and elevation of acute phase reactants were
observed. Treatment with etanercept (12.5 mg/week) was
therefore started with prompt normalisation of acute
phase reactants; hypertension and the levels of plasmatic
immunoglobulins slowly normalized. Within three years
from the beginning of the treatment, the patient is in
wellbeing. CERC1 analysis revealed the same mutations of
the brother. A third non-related child born from consan-
guineous parents at the age of 6 month presented with
facial hemiparesis. Persistent elevation of acute phase reac-
tants were also observed. At the age of 1 year the patient
presented an episode of myocarditis treated with diuretics
and antibiotics. At the age of 2 livedo reticularis occurred.
In the following years he presented a persistent elevation
of acute phase reactants and developed two episodes of
ischemic stroke High doses of steroids were were able to
control the clinical picture with elevation of acute phase
reactants at tapering. Treatment with etanercept was
therefore stared (25 mg/weekly) with prompt normaliza-
tion of acute phase reactants and persistent wellbeing after
8 month of treatment. Analysis of CERC1 gene revealed
the T360A homozygous mutation.
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Conclusion
This series of three cases enlightens the long-term
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